CURRENT NEWS

• 17.01.2022
  ImmunoPrecise Antibodies Announces Grant of Stock Options
• 14.01.2022
  Notice Regarding Results and Completion of Acquisition of Treasury Shares
• 14.01.2022
  Silvanol Product Stand in the Renovated Concept Store of the Sister Company Tonus Elast, Riga
• 14.01.2022
  Mithra Announces Positive Top-Line Results from Donesta Phase 3 Studies in Menopausal Women
• 14.01.2022
  Improved Pharma Announces Pharmaceutical R&D Efforts in 2021
• 14.01.2022
  LetsGetChecked Expands COVID-19 Offering With Antigen Testing and Virtual Observation Services to Empower Employers to Protect the Health and Wellbeing of Employees
• 14.01.2022
  VastBiome Announces Large Exploratory Prospective Data Collection to Understand Basic Science of the Microbiome and Immune Checkpoint Inhibitor Therapy
• 14.01.2022
  Medtronic Announces Results Showing Meaningful Pain Relief Using DTM Spinal Cord Stimulation Endurance Therapy
• 14.01.2022
  SERB Receives EU Approval for Voraxaze (Glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity
• 14.01.2022
  Element Further Expands Its Life Sciences Testing Business With Additional Pharmaceutical and Biotech Testing Capabilities in North America and Europe
• 14.01.2022
  ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 Special Meeting to Approve Proposed Business Combination
• 14.01.2022
  Vanda Pharmaceuticals Settles HETLIOZ Patent Litigation With MSN
• 14.01.2022
  Vivera Pharmaceuticals Issues Statement Regarding LuSys Laboratories COVID-19 Tests
• 14.01.2022
  I-Mab Announces Execution of Senior Management Team Share Purchase Plan
• 14.01.2022
  Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product
• 14.01.2022
  BioNTech and InstaDeep Collaboration Develops SARS-CoV-2 Early Warning System
• 14.01.2022
  Avicanna Enters Master Supply Agreement With Chilean Pharmaceutical Pioneer Knop Laboratorios S.A
• 14.01.2022
  Universal Ibogaine Announces World-Class Clinical Trial Partners in Advance of Clinical Trial Application or Ibogaine in Opioid Use Disorder
• 14.01.2022
  Glenmark Specialty S.A. (Switzerland) Receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and Older
• 14.01.2022
  Digital Health Leader Verana Health Secures $150M Series E Funding Round

Records per page:

Page

Total: 22551 records.